RVTYRevvity

Healthcare

$154.08+76% 1Y

$154.08

$82.2652 weeks$157.37

Is the price fair?

Watch

A demanding price: at the top of its own P/E range and rich vs its sector.

2 to watch, 1 without data

What the price assumes~+6% a year

Priced for ~6% a year FCF growth. Moderate growth expectations are priced in.

Vs its own P/E rangedearer than 93% of its own historyderived

Expensive vs its own history: P/E 73.7 vs a 30.9 median over 41 quarters (+139% vs median).

Vs sector (EV/EBIT)37.2×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jul 5, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 8% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What RVTY's price assumes

Revvity trades at 73.7× earnings against 35.2× for the median Diagnostics & Research name, more expensive than its own group.

73.7

Trailing P/E · Diagnostics & Research median 35.2 · 2.10× the median: the market pays up for this one

Price / sales: 3.83
Price / sales · today's price, trailing year to Jul 5, 2026
Free cash flow yield: 5.0%
Free cash flow yield · Diagnostics & Research median 3.7%
Growth the price implies: +5.6%
Growth the price implies · The price pays for +5.6% free cash flow growth a year for a decade; the business has delivered +54% a year over the last three.